AstraZeneca says its China operations president under investigation
It was not immediately clear whether the executive Leon Wang was in the custody of the Chinese government
Add BT as a preferred source
ASTRAZENECA’S China president is under investigation and is cooperating with Chinese authorities, the company said on Wednesday (Oct 30), sending shares down as much as 5.3%.
It was not immediately clear whether the executive Leon Wang was in the custody of the Chinese government. When asked about Wang’s whereabouts, a company spokesperson only reiterated that the executive was under investigation.
The Anglo-Swedish company has for years had one of the strongest market positions among western drugmakers in China, the world’s No 2 pharmaceuticals market behind the United States. It has invested heavily in the country, announcing plans last year to build a US$450 million factory and more recently signing a number of licensing deals with Chinese companies.
In a statement, the drugmaker said its Chinese operations were “under the leadership of the current general manager of AstraZeneca China,” without providing further details.
“If requested, AstraZeneca will fully cooperate with the investigation”, the statement read.
In September, China detained five of AstraZeneca’s current and former employees for questioning.
The company has not given details about the detention in September, and a spokesperson had no comment on Wednesday on the status of the employees being held. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Singapore at 61: How we can ensure opportunity, security and ownership for the next generation
With tech for fact-checking to cancer care, Singapore startups aim beyond home
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
Why Asean matters more than ever to the UK and Singapore
